Eddie L Jeffries

US Patent:

20070161057, Jul 12, 2007

Filed:

Sep 8, 2004

Appl. No.:

10/572054

Inventors:

Eddie Jeffries - Sterling VA, US
Charles Young - Mount Airy MD, US

International Classification:

G01N 33/569

US Classification:

435007220

Abstract:

The invention provides an efficient, sensitive, and reliable method for detection of parasites such as by efficiently extracting molecular markers or antigens using non-ionic detergents and ECL detection, and kits and compositions for performing such methods.

US Patent:

20030059839, Mar 27, 2003

Filed:

May 21, 2002

Appl. No.:

10/151295

Inventors:

Richard Obiso - Frederick MD, US
Charles Young - Mt. Airy MD, US
Eddie Jeffries - Sterling VA, US

International Classification:

G01N033/53

US Classification:

435/007100

Abstract:

A method is described for the detection, either qualitatively or quantitatively, of gastrointestinal microorganisms in samples, preferably fecal samples, using immunoassays, preferably electrochemiluminescence (ECL) immunoassays. The methods involve detection without the conventional processing steps typically required for such detection (e.g., lysing, enrichment, separation, or purification). The method comprises dilution of the sample thought to contain a specific microorganism, inactivation (e.g., heat inactivation) of the diluted sample, removal of solids from the inactivated diluted sample, and detection of the pathogen in the inactivated diluted sample, by conducting an electrochemiluminescence assay for a bound complex of antibody and antigenic derivative, thereby detecting and/or presumptively identifying the microorganism in the sample.

US Patent:

20200041526, Feb 6, 2020

Filed:

Jul 17, 2019

Appl. No.:

16/514380

Inventors:

- Incline Village NV, US
Eddie Phillip JEFFRIES - Sterling VA, US

Assignee:

PDL BIOPHARMA, INC. - Incline Village NV

International Classification:

G01N 33/68
C07K 16/18
G01N 33/543

Abstract:

Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.

US Patent:

20170192014, Jul 6, 2017

Filed:

Mar 20, 2015

Appl. No.:

15/127644

Inventors:

- Chevy Chase MD, US
Eddie Phillip JEFFRIES - Sterling VA, US

International Classification:

G01N 33/68
C07K 16/18

Abstract:

Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK1 8 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.